Amgen's Imdelltra reduced the risk of death by 40% compared to chemotherapy for small cell lung cancer patients whose disease ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today positive results from the Phase III ...

The Phase 3 DeLLphi-304 trial data presented at ASCO 2025 showed that Imdelltra® (tarlatamab-dlle) reduced the risk of death ...

Jazz Pharmaceuticals (NASDAQ:JAZZ) said on Monday that the company's late-stage study of Zepzelca in combination with ...

Amgen has detailed a positive phase 3 readout for its T-cell engager Imdelltra in previously treated small cell lung cancer ...

Results from a Phase III clinical trial published in the New England Journal of Medicine, show that patients with lung cancer ...

Amgen (NASDAQ:AMGN) today announced new interim results from the global Phase 3 DeLLphi-304 trial showing IMDELLTRA® (tarlatamab-dlle) reduced the risk of death by 40% and significantly extended ...

Patients with extensive-stage SCLC often respond to induction therapy, but the disease tends to progress rapidly after cytotoxic therapy ends, said Jared Weiss, MD, of the University of North Carolina ...

The International Air Transport Association said on Sunday it expects the amount of sustainable aviation fuel produced to ...

The BLA seeking accelerated approval for patritumab deruxtecan in previously treated, locally advanced EGFR-mutated NSCLC in ...